Nuclear NF-κB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 5974-5984

  Arun, Pattatheyil ^a   Brown, Matthew S ^a   Ehsanian, Reza ^a,b   Chen, Zhong ^a   Van Waes, Carter ^a,c  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN BCL 2; PROTEIN BCL XL; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ISOQUINOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TRANSACTIVATION; CELL NUCLEUS; DRUG ANTAGONISM; DRUG EFFECT; HEAD AND NECK TUMOR; METABOLISM; MUCOSA; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL CULTURE;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEAD AND NECK NEOPLASMS; HUMANS; ISOQUINOLINES; MUCOUS MEMBRANE; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RNA, SMALL INTERFERING; SERINE; SULFONAMIDES; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

EID: 70349675898     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1352     Document Type: Article

References (50)

1. Chang AA, Van Waes C. Nuclear factor-κB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv Otorhinolaryngol 2005;62:92-102. (Pubitemid 40014309)
2. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-6523 (Pubitemid 39297908)
3. Baldwin AS, Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683
4. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-362
5. Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev 2006;210: 171-186
6. Buss H, Dorrie A, Schmitz ML, et al. Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem 2004; 279:49571-49574 (Pubitemid 39577758)
7. Haller D, Russo MP, Sartor RB, Jobin C. IKKβ and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria- induced RelA phosphorylation and NF-κB activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002;277:38168-38178 (Pubitemid 35154670)
8. Mattioli I, Sebald A, Bucher C, et al. Transient and selective NF-κB p65 serine 536 phosphorylation induced by T cell costimulation is mediated b y IκB kinase β and controls the kinetics of p65 nuclear import. J Immunol 2004;172:6336-6344 (Pubitemid 38621242)
9. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353-30356 (Pubitemid 129576764)
10. Sakurai H, Suzuki S, Kawasaki N, et al. Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003;278:36916-36923 (Pubitemid 37140026)
11. Schwabe RF, Sakurai H. IKKβ phosphorylates p65 at S468 in transactivaton domain 2. FASEB J 2005;19:1758-1760 (Pubitemid 41429554)
12. Yang F, Tang E, Guan K, Wang CY. IKK β plays an essential role in the phosphorylation of RelA/ p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003;170:5630-5635 (Pubitemid 36617854)
13. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1: 661-671 (Pubitemid 128379244)
14. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997;89:413-424 (Pubitemid 27220886)
15. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22:1313-1324 (Pubitemid 36362695)
16. Joo JH, Jetten AM. NF-κB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. J Biol Chem 2008;283:16391-16399
17. Robinson-White AJ, Hsiao HP, Leitner WW, et al. Protein kinase A-independent inhibition of proliferation and induction of apoptosis in human thyroid cancer cells by 8-Cl-adenosine. J Clin Endocrinol Metab2008;93:1020-1029
18. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 2006;24: 261-274
19. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990;50:7093-7100
20. Jamaluddin M, Wang S, Boldogh I, Tian B, Brasier AR. TNF-α-induced NF-κB/RelA Ser (276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 2007;19:1419-1433
21. Lu SL, Herrington H, Reh D, et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006;20:1331-1342 (Pubitemid 43727593)
22. Patel V, Rosenfeldt HM, Lyons R, et al. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis 2007;28:1145-1152 (Pubitemid 47062672)
23. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 2004;64:8804-8807 (Pubitemid 39665480)
24. Thomas SM, Bhola NE, Zhang Q, et al. Crosstalk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-11839 (Pubitemid 46094195)
25. Ondrey FG, Dong G, Sunwoo J, et al. Constitutive activation of transcription factors NF-(κ)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and pro-angiogenic cytokines. Mol Carcinog 1999;26:119-129
26. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB and aberrant NF-κB activation by serum factor(s) in head and neck squamous cell carcinoma cells. Cancer Res 2006;66:6722-6731 (Pubitemid 44085630)
27. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-1379 (Pubitemid 29282941)
28. Younes F, Quartey EL, Kiguwa S, Partridge M. Expression of TNF and the 55-kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral Dis 1996;2:25-31. (Pubitemid 126602146)
29. Sung MH, Bagain L, Chen Z, et al. Dynamic effect of bortezomib on nuclear factor-κB activity and gene expression in tumor cells. Mol Pharmacol 2008;74:1215-1222
30. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor Bortezomibs ensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6:37-50. (Pubitemid 46206667)
31. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase- 2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994 (Pubitemid 29135955)
32. Mestre JR, Chan G, Zhang F, et al. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci 1999;889:62-71.
33. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24: 792-799 (Pubitemid 34857307)
34. Zhang PL, Pellitteri PK, Law A, et al. Overexpression of phosphorylated nuclear factor-κ B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 2005;18:924-932
35. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS, Jr. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-24116
36. Edelblum KL, Goettel JA, Koyama T, McElroy SJ, Yan F, Polk DB. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-κB. J Biol Chem 2008;283:29485-29494
37. Nelson DE, Ihekwaba AE, Elliott M, et al. Oscillations in NF-κB signaling control the dynamics of gene expression. Science 2004;306:704-708 (Pubitemid 39440922)
38. Nowak DE, Tian B, Jamaluddin M, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-κB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008;28:3623-3638 (Pubitemid 351732900)
39. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-5799
40. ZongWX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα- induced apoptosis. Genes Dev 1999;13:382-387 (Pubitemid 29108753)
41. Allen C, Duffy S, Teknos T, et al. Nuclear factor-κBrelated serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal cancer. Clin Cancer Res 2007;13:3182-3190 (Pubitemid 46944900)
42. Scovassi AI, Stivala LA, Rossi L, Bianchi L, Prosperi E. Nuclear association of cyclin D1 in human fibroblasts: tight binding to nuclear structures and modulation by protein kinase inhibitors. Exp Cell Res 1997;237:127-134 (Pubitemid 27528037)
43. Nesterova MV, Cho-Chung YS. Chemoprevention with protein kinase A RIα antisense in DMBA-mammary carcinogenesis. Ann N Y Acad Sci 2005;1058:255-264
44. Yokozaki H, Budillon A, Tortora G, et al. An antisense oligodeoxynucleotide that depletes RI α subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993;53:868-872 (Pubitemid 23077876)
45. Bianco C, Bianco R, Tortora G, et al. Anti-tumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6: 4343-4350 (Pubitemid 30840187)
46. Agrawal S, Kandimalla ER, Yu D, et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIα subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol 2002;21:65-72.
47. Khor LY, Bae K, Al-Saleem T, et al. Protein kinase A RI-α predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. Int J Radiat Oncol Biol Phys 2008;71:1309-1315
48. Manna SK, Manna P, Sarkar A. Inhibition of RelA phosphorylation sensitizes apoptosis in constitutive NF-κB-expressing and chemoresistant cells. Cell Death Differ 2007;14:158-170 (Pubitemid 44911903)
49. Zentella de Piña M, Vαzquez-Meza H, Agundis C, et al. Inhibition of cAMP-dependent protein kinase A: a novel cyclo-oxygenase- independent effect of non-steroidal anti-inflammatory drugs in adipocytes. Auton Autacoid Pharmacol 2007; 27:85-92. (Pubitemid 46496067)
50. Bock JM, Menon SG, Goswami PC, et al. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog 2007;46:857-864